Peptides are moving towards approval. This is the first domino in a vastly consequential chain of events that ends with $HIMS being worth $2,000 per share intrinsically by 2030. 1/ BPC-157 and other generic peptides get approved. Millions of people try them. They see results. And then they ask the obvious question: what else can I take? 2/ They ask that question on the platform that already serves them. $HIMS is one of the largest D2C healthcare platforms on Earth, with a vertically integrated supply chain. Vertical integration wins on price. Price wins the customer. 3/ Every customer becomes a source of biomarker data. And that data gets deeper and more exhaustive every year: more patients, more panels, more longitudinal measurements, more before-and-after pairs. Every new customer makes the machine smarter. Every improvement in the machine attracts more customers. 4/ Eventually, the dataset becomes so exhaustive that $HIMS AI can design personalised peptides for virtually anyone. The objective: optimal patient outcomes at a fraction of the cost of competing solutions. Healthcare stops being about prescribing the same molecule to millions of people. It becomes about designing the optimal intervention for each individual. 5/ This is the scenario that takes $HIMS to $2,000 in intrinsic value per share by 2030. In everyone's eyes, it becomes the platform that unlocks an entirely new AI scaling law: life extension per token. It turns the pharmaceutical industry upside down. Traditional drug discovery becomes increasingly obsolete as value migrates towards the AI trained on the largest, deepest and highest-quality longitudinal biomarker dataset. The molecule becomes the output. The intelligence that designs it becomes the asset. 6/ This sends everyone into a race to build or access that intelligence. If you don't own the AI, you're increasingly forced to depend on it. As a pharmaceutical supplier, because competitors using it can design better interventions at lower costs. As a customer, because people using it may achieve better health outcomes and ultimately live longer than those who don't. 7/$HIMS becomes the most valuable subscription service on Earth as its AI grows increasingly predictive. Just as operating without $PLTR can create a massive competitive disadvantage, increasingly comparable to operating without electricity, living outside the $HIMS OS could mean losing access to the most consequential value creation machine in healthcare. Except this time, the output isn't just productivity or economic efficiency. It's additional years of human life.

Peptides are moving towards approval. This is the first domino in a vastly consequential chain of events that ends up in $HIMS being worth $2,000 per share intrinsically by the year 2030. 1/ BPC-157 and the other generic peptides get approved. Millions of people try them. They see results. Then they ask the obvious question: what else can I take? 2/ They ask it on the platform that already has them. $HIMS is the largest D2C healthcare platform on Earth, and the only one with a vertically integrated supply chain. Vertical integration wins on price:value. Price:value wins the customer. 3/ Every customer becomes biomarker data. And the biomarker data gets deeper and more exhaustive every year: more patients, more panels, more before-and-after pairs. 4/ Eventually the data is so exhaustive that $HIMS AI can design personalised peptides for anyone. Optimal patient outcomes, at a fraction of the cost of anyone else in the market. 5/ This is the scenario that takes $HIMS to $2,000 intrinsic value by 2030. In everyone’s eyes, it becomes the platform that unlocks the new AI scaling law: life extension per token. It inverts the entire industry on its head: "drug discovery" gets immediately deprecated and all value accrues to the single AI trained with the most and highest quality biomarker data. 6/ This sends everyone on a race to space: if you don't own this AI, you're forced to succumb to it both as a pharma supplier and as a customer, because not using this AI means others beat you in selling drugs and you just don't live as long as customer, respectively. 7/ It becomes the most valuable subscription service on Earth as the AI gets increasingly predictive. Just like not running $PLTR today is a massive disadvantage, increasingly comparable to not using electricity, not running on the $HIMS OS means you don't have access to the core value creation machine that literally allows anyone in the industry to stay alive.